Investigational drug · Phase 2
ISLA101
Also called: fenretinide
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dengue.
Phase 2Last checked: Nov 19, 2026Latest source record: Oct 24, 2025 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 2
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
1
Any phase or sponsor naming "ISLA101"
First trial start
2024
Sep 5, 2024
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ISLA101", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dengue
Largest trials
Live from ClinicalTrials.gov: studies naming "ISLA101" as an intervention, largest first.
Island PharmaceuticalsIndustry
NCT06528457 · 15 participants · Start Sep 5, 2024 · Primary completion May 21, 2025
Drug: ISLA101; Dengue 1 Live Virus Human Challenge (DENV-1-LVHC) · For: Dengue
Sites: East Syracuse, New York
Newest research
PubMed records naming it or its code names, newest first.
- Aerosolizable Janus Protein Nanoparticles for Secondary and Tertiary Lung Cancer Chemoprevention.
Chang A, Wang D, Shea F, et al. · ACS Appl Bio Mater 2026
- Fenretinide in cancer therapy and chemoprevention: past, present and future.
Verachi P, Francescangeli F, Dattilo R, et al. · Cancer Drug Resist 2026
- Synthesis and Biological Evaluation of a New Dihydroceramide Desaturase Inhibitor for the Treatment of MASLD.
Cevallos K, Abad JL, Babiy B, et al. · J Med Chem 2026
- Positive net antiviral benefit of bexarotene against patient-derived archetype and rearranged BK polyomavirus isolates.
Feld P, Lauterbach-Rivière L, Götz KM, et al. · Antiviral Res 2026
- Integrative genomic and multi-omics analyses identify oxidative stress-related pathways and druggable targets for tinnitus.
Han J, Cao Y, Zhang C, et al. · Front Neurol 2026
- Co-delivery of fenretinide and perillyl alcohol for breast cancer pharmacological prevention through nanostructured lipid carriers: characterization, cellular studies and in vivo localization.
Malagó ID, Salata GC, Duarte Marques BV, et al. · Int J Pharm 2026
Also in development for Dengue
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.